an atypical protein kinase that functions as a transcriptional coactivator. Mediates transcriptional regulation by interaction with the Kruppel-associated box (KRAB) repression domain found in many transcription factors. Binds to the negative regulatory domain of c-Myb and negatively regulates the c-Myb-dependent trans-activation. Localizes to the nucleus and is thought to associate with specific chromatin regions. Phosphorylated in an ATM-dependent manner following double-strand breaks. Its phosphorylation in response to DNA damage leads to chromatin relaxation. A member of the tripartite motif family. The tripartite motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. Note: This description may include information from UniProtKB.
Protein type: Ubiquitin conjugating system; Nuclear receptor co-regulator; Protein kinase, atypical; Ubiquitin ligase; Kinase, protein; Ligase; EC 6.3.2.-; Transcription, coactivator/corepressor; ATYPICAL group; TIF1 family
Molecular Function: protein binding; DNA binding; zinc ion binding; sequence-specific DNA binding; ubiquitin protein ligase binding; transcription coactivator activity; ubiquitin-protein ligase activity; transcription corepressor activity; transcription factor activity; protein kinase activity
Biological Process: transcription initiation from RNA polymerase II promoter; convergent extension involved in axis elongation; positive regulation of DNA repair; protein amino acid autophosphorylation; positive regulation of transcription, DNA-dependent; protein ubiquitination; negative regulation of transcription from RNA polymerase II promoter; DNA repair; protein oligomerization; protein sumoylation; positive regulation of transcription factor import into nucleus; epithelial to mesenchymal transition; innate immune response; gene expression; negative regulation of transcription, DNA-dependent
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.